This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Edwards Lifesciences to Report on Lowered Outlook

NEW YORK ( TheStreet) -- This has been a busy week of earnings reports as many large cap companies crowd the headlines and anxious shareholders react to news from the earnings confessional.

Some of these reports, as well as the political circus in the U.S. and even the baseball championships have left many shareholders, voters and sports fans feeling the pounding of that most important of all pumps, our incredible hearts.

With the ongoing process of aging comes new medical issues and coronary challenges. Here in the U.S., more than 1,000 "baby boomers" turn 65 each day. The oldest of that large demographic group (estimated at around 75 million people) will soon be turning 67 in 2013.

The breakthroughs in cardiac technologies and the science of keeping the heart pumping reliably are becoming more important with each passing year.

One of the companies focusing on this critically important area of health care for almost 13 years is Edwards Lifesciences (EW - Get Report) which reports earnings Friday.

Irvine, Calif.-based Edwards Lifesciences provides products and technologies used to treat advanced cardiovascular diseases. Edwards' expertise involves providing many of the vital parts that are used during cardiac surgery procedures. They appear to be one of the most successful "specialists" in creating minimally invasive surgery products.

Beyond that EW manufactures and sells various other vascular devices consisting of balloon-tipped, catheter-based embolectomy products, plus surgical clips and clamps. When it comes to the medical products needed for the repair of the human heart EW appears to provide them or is working on providing them.

You can learn about EW's specialties at their educational web site. You're sure to come away learning not only about this company but of many medical advances that have been made in the science of keeping our "tickers ticking."

Jim Cramer and Stephanie Link actively manage a real money portfolio for his charitable trust -- enjoy advance notice of every trade, full access to the portfolio, and deep coverage of the latest economic events and market movements.

As EW prepares to report third-quarter results, it's important to remember that the company has guided lower in the weeks preceding. Analysts lowered their consensus estimate of earnings per share from 60 cents to around 56 cents. That would still represent a 47% increase over the year-ago quarter when the company reported earnings of 38 cents per share.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
EW $107.20 -1.60%
MDT $79.79 0.43%
AAPL $95.03 -2.90%
FB $117.52 7.90%
GOOG $691.20 -2.10%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs